Analysts take a look at Zogenix, Inc. (NASDAQ:ZGNX) having this to say.

May 15, 2018 - By Clifton Ray

Zogenix, Inc. (NASDAQ:ZGNX) Logo

Zogenix, Inc. (NASDAQ:ZGNX) Ratings Coverage

Among 2 analysts covering Zogenix (NASDAQ:ZGNX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zogenix had 2 analyst reports since November 27, 2017 according to SRatingsIntel. Leerink Swann maintained the stock with “Outperform” rating in Friday, February 23 report. The firm earned “Buy” rating on Monday, November 27 by JMP Securities. Below is a list of Zogenix, Inc. (NASDAQ:ZGNX) latest ratings and price target changes.

23/02/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $50 New Target: $54 Maintain
27/11/2017 Broker: JMP Securities Rating: Buy New Target: $56.0 Initiate

The stock decreased 1.03% or $0.4 during the last trading session, reaching $38.3. About 490,939 shares traded. Zogenix, Inc. (NASDAQ:ZGNX) has risen 253.21% since May 15, 2017 and is uptrending. It has outperformed by 241.66% the S&P500.

Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. The company has market cap of $1.35 billion. The companyÂ’s lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. It currently has negative earnings. It also develops Relday, an injectable formulation of risperidone to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older.

More notable recent Zogenix, Inc. (NASDAQ:ZGNX) news were published by: which released: “Report: Exploring Fundamental Drivers Behind Urban Edge Properties, FLIR, Zogenix, Watts Water Technologies …” on April 25, 2018, also with their article: “Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9” published on May 04, 2018, published: “Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)” on May 01, 2018. More interesting news about Zogenix, Inc. (NASDAQ:ZGNX) were released by: and their article: “Despite Losing $88 Million in Q2, This Pot Stock Still Has More Cash Than Any of Its Peers” published on May 14, 2018 as well as‘s news article titled: “Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome” with publication date: April 27, 2018.

Zogenix, Inc. (NASDAQ:ZGNX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.